share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  09/03 08:06

Moomoo AI 已提取核心信息

On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") announced the top-line results of its SYCAMORE trial, a Phase 2 study for REC-994 in symptomatic cerebral cavernous malformation (CCM) patients. The trial met its primary endpoint of safety and tolerability and showed encouraging trends in MRI-based exploratory efficacy measures at the highest dose. Recursion plans to advance the development of REC-994 for CCM treatment and intends to discuss further clinical studies with the FDA. Additionally, Recursion has entered into a transaction agreement with Exscientia plc ("Exscientia"), which, subject to conditions including stockholder approvals, will result in Recursion acquiring Exscientia. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts anticipated over the next 18 months. The transaction is projected to close by early 2025, with Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined entity. The merger aims to leverage technology to discover and develop high-quality medicines efficiently and at scale.
On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") announced the top-line results of its SYCAMORE trial, a Phase 2 study for REC-994 in symptomatic cerebral cavernous malformation (CCM) patients. The trial met its primary endpoint of safety and tolerability and showed encouraging trends in MRI-based exploratory efficacy measures at the highest dose. Recursion plans to advance the development of REC-994 for CCM treatment and intends to discuss further clinical studies with the FDA. Additionally, Recursion has entered into a transaction agreement with Exscientia plc ("Exscientia"), which, subject to conditions including stockholder approvals, will result in Recursion acquiring Exscientia. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts anticipated over the next 18 months. The transaction is projected to close by early 2025, with Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined entity. The merger aims to leverage technology to discover and develop high-quality medicines efficiently and at scale.
2024年9月3日，Recursion Pharmaceuticals公司（“Recursion”）宣布其SYCAMORE试验的顶线结果，该试验是REC-994在症状性脑血管畸形（CCM）患者中的2期研究。该试验在安全性和耐受性方面达到了主要终点，并在最高剂量下显示了基于MRI的探索性疗效指标的令人鼓舞的趋势。Recursion计划推进REC-994用于CCM治疗的开发，并打算与FDA讨论进一步的临床研究。此外，Recursion与Exscientia plc（“Exscientia”）达成了一项交易协议，条件包括股东批准，Recursion将收购Exscientia。合并后的公司预计将拥有多...展开全部
2024年9月3日，Recursion Pharmaceuticals公司（“Recursion”）宣布其SYCAMORE试验的顶线结果，该试验是REC-994在症状性脑血管畸形（CCM）患者中的2期研究。该试验在安全性和耐受性方面达到了主要终点，并在最高剂量下显示了基于MRI的探索性疗效指标的令人鼓舞的趋势。Recursion计划推进REC-994用于CCM治疗的开发，并打算与FDA讨论进一步的临床研究。此外，Recursion与Exscientia plc（“Exscientia”）达成了一项交易协议，条件包括股东批准，Recursion将收购Exscientia。合并后的公司预计将拥有多样化的临床和近临床项目组合，未来18个月内预计将有大约10个临床结果。预计这项交易将于2025年初完成，Recursion股东将持有合并实体的大约74%，Exscientia股东将持有合并实体的大约26%。此次合并旨在利用科技高效、规模化地发现和开发高质量药物。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间